Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
VTYX 
Ventyx Biosciences Inc (VTYX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/17/2025: VTYX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
9 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $11.5
1 Year Target Price $11.5
| 5 | Strong Buy |
| 1 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -58.86% | Avg. Invested days 18 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 279.53M USD | Price to earnings Ratio - | 1Y Target Price 11.5 |
Price to earnings Ratio - | 1Y Target Price 11.5 | ||
Volume (30-day avg) 9 | Beta 1.01 | 52 Weeks Range 0.78 - 4.12 | Updated Date 10/18/2025 |
52 Weeks Range 0.78 - 4.12 | Updated Date 10/18/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.66 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -30.23% | Return on Equity (TTM) -48.56% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 53055068 | Price to Sales(TTM) - |
Enterprise Value 53055068 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -22.93 | Shares Outstanding 71308518 | Shares Floating 53555549 |
Shares Outstanding 71308518 | Shares Floating 53555549 | ||
Percent Insiders 4.11 | Percent Institutions 68.66 |
Upturn AI SWOT
Ventyx Biosciences Inc
Company Overview
History and Background
Ventyx Biosciences is a clinical-stage biopharmaceutical company focused on developing and commercializing oral small molecule therapies for autoimmune and inflammatory diseases. Founded in 2019, Ventyx has rapidly advanced its pipeline, aiming to address significant unmet needs in immunology.
Core Business Areas
- TYK2 Inhibitor Program: Ventyx's lead program focuses on inhibitors of tyrosine kinase 2 (TYK2), a key signaling molecule in the IL-23/IL-12 and interferon pathways, targeting diseases like psoriasis, psoriatic arthritis, and Crohn's disease.
- NLRP3 Inhibitor Program: Ventyx is developing NLRP3 inhibitors to target inflammatory diseases driven by the NLRP3 inflammasome, such as cardiovascular and neurodegenerative diseases.
- S1P1R Modulator Program: Ventyx also is focused on S1P1R modulators, for various diseases, including autoimmune diseases.
Leadership and Structure
Ventyx Biosciences is led by a management team with experience in drug development and commercialization. The company has a board of directors overseeing its strategic direction.
Top Products and Market Share
Key Offerings
- VTX958 (TYK2 inhibitor): An oral, selective TYK2 inhibitor in Phase 2 clinical trials for psoriasis and psoriatic arthritis. Competitors include BMS (Sotyktu) and other companies developing TYK2 inhibitors. Currently there is no market share data available as it is still in clinical development.
- VTX3232 (NLRP3 inhibitor): An oral NLRP3 inhibitor in Phase 1 clinical trials. Competitors include companies developing NLRP3 inhibitors for various inflammatory conditions. Currently there is no market share data available as it is still in clinical development.
Market Dynamics
Industry Overview
The biopharmaceutical industry focusing on autoimmune and inflammatory diseases is characterized by high growth and intense competition. The demand for novel therapies is driven by the prevalence of these diseases and limitations of existing treatments.
Positioning
Ventyx Biosciences is positioned as an innovator in developing oral small molecule therapies for immunology. Its competitive advantage lies in its focus on validated targets and its pipeline of differentiated molecules.
Total Addressable Market (TAM)
The TAM for autoimmune and inflammatory disease therapies is estimated to be over $100 billion. Ventyx is positioning to get a part of this huge market.
Upturn SWOT Analysis
Strengths
- Promising clinical pipeline targeting large market
- Experienced management team
- Strong intellectual property position
- Oral small molecule approach offers convenience over biologics
Weaknesses
- Clinical trial risks and regulatory hurdles
- Dependence on successful development of pipeline assets
- Limited commercialization experience
- High cash burn rate
Opportunities
- Potential for strategic partnerships and collaborations
- Expansion into new indications
- Positive clinical trial results leading to regulatory approval
- Acquisition by larger pharmaceutical companies
Threats
- Competition from established pharmaceutical companies
- Failure to achieve positive clinical trial results
- Changes in regulatory landscape
- Generic competition after loss of exclusivity
Competitors and Market Share
Key Competitors
- BMY
- PFE
- ABBV
Competitive Landscape
Ventyx faces intense competition from established pharmaceutical companies with significant resources and expertise. Ventyx's success depends on its ability to differentiate its therapies and demonstrate clinical superiority.
Growth Trajectory and Initiatives
Historical Growth: Ventyx's growth has been characterized by the advancement of its clinical pipeline and expansion of its research and development activities.
Future Projections: Future growth is dependent on the successful completion of clinical trials and potential regulatory approvals. Analyst estimates vary widely depending on the perceived likelihood of success.
Recent Initiatives: Recent initiatives include the initiation of Phase 2 clinical trials for VTX958 and advancement of other pipeline programs.
Summary
Ventyx Biosciences is a promising clinical-stage biopharmaceutical company focused on developing innovative oral small molecule therapies for autoimmune and inflammatory diseases. The company's pipeline of differentiated molecules and experienced management team are strengths, but clinical trial risks and competition pose challenges. Successful clinical trial results and potential partnerships could drive future growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- ClinicalTrials.gov
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Ventyx Biosciences Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2021-10-21 | Founder, CEO, President & Director Dr. Raju S. Mohan Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 81 | Website https://ventyxbio.com |
Full time employees 81 | Website https://ventyxbio.com | ||
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for Crohn's disease. It is also developing Tamuzimod, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor that is in Phase 2a trial for patients with early Parkinson's disease and is in Phase 2 trial for patients with obesity and additional risk factors for cardiovascular disease. Ventyx Biosciences, Inc. was incorporated in 2018 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.